Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mohammed Aldakkak
Institutions:
Medical College of Wisconsin,
Medical College of Wisconsin Cancer Center
Observed institutions:
Medical College of Wisconsin,
Medical College of Wisconsin Cancer Center
ORCID:
0009-0001-2855-3278
Observed ORCID:
0009-0001-2855-3278
OpenAlex ID:
A5138792067
Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
2026
·
Daniel Dorbin
, Juliannie Herrera
, et al.
·
Cancer Research
·
4
PDF
Abstract B123: Oncostatin M receptor (OSMR) is a tumor-selective target in pancreatic ductal adenocarcinoma: Quantitative expression in primary and metastatic patient tumors
2026
·
Naveenkumar Chandrashekhar
, Edward Opichka
, et al.
·
Cancer Research
Supplementary Figure 4 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Table 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbs
, et al.
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 4 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Data from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Table 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
2026
·
Mandana Kamgar
, G. Aaron Hobbes
, et al.
Show more works
View as search
Works count:
15
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type